Current clinical applications of AAV-mediated gene therapy
Molecular Therapy · 2025-06 · 33 (6) · 2479-2516
DOI: 10.1016/j.ymthe.2025.04.045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025-06. Verfasst von Barry J Byrne und 27 weiteren Autor:innen. Beteiligte Einrichtung: Powell Gene Therapy Center, University of Florida College of Medicine, Gainesville, FL, USA; Department of Pediatrics, University of Florida College …. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 399 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NINDS NIH HHS, NCBDD CDC HHS.
Abstract (Originalsprache)
Currently, there are an estimated 8,000 genetic disorders that cumulatively affect approximately 10% of the population. Even among the 5% of patients with genetic disease that have treatment options, these therapeutics rarely address the underlying cause of disease but rather focus on managing or modifying symptoms and typically require recurrent, lifelong therapy. A therapeutic approach to genetic disease that in vivo delivers a functional copy of the aberrant gene is an intuitive solution that has thus far taken 3 decades to reduce to clinical practice, predominantly using adeno-associated viral (AAV) vectors. Among available viral and non-viral gene delivery approaches, AAV vectors remain the most efficient means for in vivo delivery of DNA to the nucleus. AAV vectors now constitute a bone fide novel therapeutic drug class composed of seven US Food and Drug Administration-approved products with over 10-fold more in clinical development for an expanding number of disease indications and an identified list of problems to overcome for widespread clinical application. Here, we review current progress in clinical AAV gene therapy, including for neuromuscular disorders, hemophilia, primary cardiovascular disorders, or disorders with cardiovascular manifestations, lysosomal storage disorders, mucopolysaccharide disorders, primary central nervous systemic disorders, and ocular disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Powell Gene Therapy Center, University of Florida College of Medicine, Gainesville, FL, USA; Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA. Electronic address: barry.byrne@ufl…
- Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics and Neurology, The Ohio State University, Columbus, OH, USA.
- Clinical In Vivo Gene Therapy, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Philadelphia, PA, USA.
- Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
- Department of Neurology, University of Massachusetts Chan School of Medicine, Worcester, MA, USA.
- Department of Neurology and Center for Inherited Muscle Research, Virginia Commonwealth University, Richmond, VA, USA.
Förderung
- NCATS NIH HHS
- NINDS NIH HHS
- NCBDD CDC HHS
- AHRQ HHS
- FDA HHS
- NICHD NIH HHS
- NEI NIH HHS
- National Institute of Child Health and Human Development
Zitieren
APA
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C., Carrig, S., Rossano, J. W., Greenberg, B., Lalaguna, L., Lara-Pezzi, E., Subramony, S., Corti, M., Mercado-Rodriguez, C., Leon-Astudillo, C., Ahrens-Nicklas, R., …, & George, L. A. (2025). Current clinical applications of AAV-mediated gene therapy. Molecular Therapy, 33(6), 2479-2516. https://doi.org/10.1016/j.ymthe.2025.04.045
Vancouver
Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D'Ambrosio ES, et al. Current clinical applications of AAV-mediated gene therapy. Molecular Therapy. 2025;33(6):2479-2516. doi:10.1016/j.ymthe.2025.04.045
BibTeX
@article{Byrne2025,
author = {Byrne, Barry J and Flanigan, Kevin M and Matesanz, Susan E and Finkel, Richard S and Waldrop, Megan A and D'Ambrosio, Eleonora S and Johnson, Nicholas E and Smith, Barbara K and Bönnemann, Carsten and Carrig, Sean and Rossano, Joseph W and Greenberg, Barry and Lalaguna, Laura and Lara-Pezzi, Enrique and Subramony, Sub and Corti, Manuela and Mercado-Rodriguez, Claudia and Leon-Astudillo, Carmen and Ahrens-Nicklas, Rebecca and Bharucha-Goebel, Diana and Gao, Guangping and Gessler, Dominic J and Hwu, Wuh-Liang and Chien, Yin-Hsiu and Lee, Ni-Chung and Boye, Sanford L and Boye, Shannon E and George, Lindsey A},
title = {Current clinical applications of AAV-mediated gene therapy},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {6},
pages = {2479--2516},
doi = {10.1016/j.ymthe.2025.04.045}
}
EUVIMED